RaySearch Laboratories Dirección

Dirección controles de criterios 4/4

RaySearch Laboratories' El consejero delegado es Johan Lof , nombrado en Jan 2000, tiene un mandato de 24.08 años. la remuneración anual total es SEK6.90M , compuesta por 84.9% salario y 15.1% primas, incluidas acciones y opciones de la empresa. posee directamente 16.51% de las acciones de la empresa, por valor de SEK519.16M . La antigüedad media del equipo directivo y del consejo de administración es de 5.3 años y 20.4 años respectivamente.

Información clave

Johan Lof

Chief Executive Officer (CEO)

kr6.9m

Compensación total

Porcentaje del salario del CEO	84.9%
Permanencia del CEO	24.3yrs
Participación del CEO	16.5%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	20.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Johan Lof en comparación con los beneficios de RaySearch Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	kr82m
Sep 30 2023	n/a	n/a	kr64m
Jun 30 2023	n/a	n/a	kr53m
Mar 31 2023	n/a	n/a	kr22m
Dec 31 2022	kr7m	kr6m	kr24m
Sep 30 2022	n/a	n/a	-kr6m
Jun 30 2022	n/a	n/a	-kr38m
Mar 31 2022	n/a	n/a	-kr35m
Dec 31 2021	kr7m	kr6m	-kr47m
Sep 30 2021	n/a	n/a	-kr46m
Jun 30 2021	n/a	n/a	-kr50m
Mar 31 2021	n/a	n/a	-kr42m
Dec 31 2020	kr7m	kr6m	-kr9m
Sep 30 2020	n/a	n/a	kr24m
Jun 30 2020	n/a	n/a	kr43m
Mar 31 2020	n/a	n/a	kr74m
Dec 31 2019	kr8m	kr6m	kr50m
Sep 30 2019	n/a	n/a	kr64m
Jun 30 2019	n/a	n/a	kr85m
Mar 31 2019	n/a	n/a	kr84m
Dec 31 2018	kr8m	kr5m	kr79m
Sep 30 2018	n/a	n/a	kr118m
Jun 30 2018	n/a	n/a	kr104m
Mar 31 2018	n/a	n/a	kr103m
Dec 31 2017	kr9m	kr5m	kr118m

Compensación vs. Mercado: Johan($USD668.66K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD1.01M).

Compensación vs. Ingresos: La compensación de Johan ha sido consistente con los resultados de la empresa en el último año.

CEO

Johan Lof (54 yo)

24.3yrs

Permanencia

kr6,899,000

Compensación

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Lof	Founder	24.3yrs	kr6.90m	16.51% SEK 656.7m
Annika Henriksson	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Kjell Eriksson	Head of Research & Chief Science Officer	8.6yrs	sin datos	0.070% SEK 2.8m
Petra Jansson	General Counsel	6.8yrs	sin datos	sin datos
Peter Kemlin	Director of Sales & Marketing	no data	sin datos	0.0041% SEK 162.3k
Tove Alteborg	Global Human Resource Manager	less than a year	sin datos	sin datos
Bjorn Hardemark	Deputy Chief Executive Officer	8.6yrs	sin datos	0.052% SEK 2.1m
Fredrik Lofman	Head of Machine Learning	4.3yrs	sin datos	0.0041% SEK 162.3k
Marc Mlyn	President & CEO of RaySearch Americas	2.3yrs	sin datos	sin datos

5.5yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: 0GRZEl equipo directivo de la empresa es veterano y experimentado (6.4 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Lof	Founder	24.3yrs	kr6.90m	16.51% SEK 656.7m
Hans Wigzell	Independent Chairman of Board	19.9yrs	kr705.00k	sin datos
Carl Bergendal	Independent Director	24.3yrs	kr400.00k	3.39% SEK 134.7m
Radhe Mohan	Member of Scientific Advisory Board	21.3yrs	sin datos	sin datos
Anders Forsgren	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anders Brahme	Member of Scientific Advisory Board	no data	sin datos	3.79% SEK 150.8m
David Jaffray	Member of Scientific Advisory Board	no data	sin datos	sin datos
Britta Wallgren	Independent Director	5.9yrs	kr300.00k	0.020% SEK 812.1k
Gunther Marder	Independent Director	1.4yrs	kr193.00k	0.20% SEK 8.1m

20.6yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: 0GRZLos consejos de administración de la empresa son veteranos y experimentados ( 20.4 años de permanencia media en el cargo).

RaySearch Laboratories Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Recent updates

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

Second quarter 2023 earnings released

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released

Now 29% undervalued after recent price drop

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold kr20m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold kr5.6m worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

New 90-day high: kr93.60

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Revenue misses expectations

RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021

RaySearch Laboratories AB (publ) Announces University Medical Center Maribor in Slovenia Became the 700th Customer to Select RayStation

New 90-day high: kr91.55

RaySearch Receives New Order from Centre Antoine Lacassagne for RayStation in France

RaySearch Laboratories AB (Publ) Announces the Release of the First Version of the Treatment Control System (TCS) Raycommand

RaySearch Laboratories AB (publ) Announces Expansion of the Advanced Treatment Planning System Raystation

New 90-day high: kr88.20

RaySearch Laboratories AB (Publ) Launches Raystation® 10B for Brachytherapy Planning and New Gpu Monte Carlo Algorithm

RaySearch Laboratories AB (publ) Shares News of the Latest Release of Oncology Information System RayCare®

RaySearch Laboratories Introduction of RayIntelligence and the latest releases of RayStation and RayCare at ESTRO 2020